Esperion Therapeutics, a developer of small molecule therapies for the treatment of cardiometabolic disorders, has named Tim Mayleben as the new president and CEO of the company. Roger Newton, Ph.D., FAHA, who is the founder of Esperion and has been serving as its president and CEO, will become executive chairman and chief scientific officer.

Most recently, Mayleben served as president and CEO at Aastrom Biosciences. Previously, he was an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors; president, COO and a director of NightHawk Radiology; and COO and CFO of the original Esperion Therapeutics, which Newton also founded.

While at Esperion, Mayleben has raised more than $200 million in venture and institutional equity capital and negotiated the sale of Esperion to Pfizer for $1.3 billion in February 2004.